Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase NA 1Phase 4 1Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Head and Neck Neoplasms 2Uterine Cervical Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gallbladder Neoplasms 1Extensive Stage Small Cell Lung Carcinoma 1Epstein-Barr Virus Infections 1Carcinoma, Squamous Cell 1Advanced Glioblastoma 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 5pembrolizumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Docetaxel 4Gemcitabine 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cemiplimab 2auricularum 2Specimen Handling 2Ramucirumab 2Radiotherapy 2Leucovorin 2Erlotinib Hydrochloride 2Drug Therapy 2Calcium Dobesilate 2pertuzumab 1oblimersen 1maimendongtang 1endostar protein 1cyclopropapyrroloindole 1cediranib 1aumolertinib 1anamorelin 1Vitamin B 12 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Radiotherapy, Intensity-Modulated × Clear all
NCT05994339 2023-08-29

Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer

Laibin People's Hospital

Phase 2/3 Unknown
40 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡